Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers
Science Advances · 2026-06-05 · 12 (23)
DOI: 10.1126/sciadv.aeb3726 ↗At a glance
Journal article in Science Advances, published on 2026-06-05. Written by Jiwon Kim and 11 co-authors. Institution: Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Major MEDLINE topics: DNA Damage, DNA-Binding Proteins, Transcription Factors, Neoplasms. 42 references. The full text is freely available in PubMed Central. Funded by: Ministry of Health and Welfare, Seoul National University, Ministry of Science and ICT, South Korea.
Abstract (original language)
ARID1A (AT-rich interaction domain 1A), a key subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex, is frequently mutated in cancers. However, effective clinical treatments for patients with this mutation are limited, highlighting a need for therapeutic strategies. Here, we identify Werner syndrome adenosine 5′-triphosphate–dependent helicase (WRN) as a critical vulnerability in ARID1A -mutated cancers. Upon genetic and pharmacological inhibition of WRN, ARID1A -mutated cells had defective checkpoint kinase 1 (Chk1)-mediated DNA damage signaling, resulting in compensatory checkpoint kinase 2 (Chk2) activation, leading to G 1 phase arrest and apoptosis, whereas ARID1A -proficient cells underwent Chk1-dependent G 2 -M arrest. Additional p21 inhibition in the context of WRN suppression promoted cell cycle reentry of G 1 -arrested ARID1A -mutated cells, resulting in enhanced cytotoxicity through mitotic catastrophe. The antitumor efficacy of WRN inhibition alone and in combination with p21 inhibition was validated using cell line–based xenograft and patient-derived xenograft mouse models. Our findings define WRN as a selective therapeutic target in ARID1A -mutated cancers and suggest a combinatorial strategy of WRN and p21 inhibition as a therapeutic approach.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Department of Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea.
ORCID profiles: Jiwon Kim, Jaeik Oh, Seungjae Shin, Soo-Jin Lee, Yoojin Yang, Hae Rim Jung, Sung-Yup Cho
Funding
- Ministry of Health and Welfare
- Seoul National University
- Ministry of Science and ICT, South Korea
Cite
APA
Kim, J., Oh, J., Jang, D., Shin, S., Lee, S. J., Lee, S. E., Yang, Y., Kim, D., Choi, A. J., Jung, H. R., Oh, Y., & Cho, S. Y. (2026). Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers. Science Advances, 12(23). https://doi.org/10.1126/sciadv.aeb3726
Vancouver
Kim J, Oh J, Jang D, Shin S, Lee SJ, Lee SE, et al. Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers. Science Advances. 2026;12(23). doi:10.1126/sciadv.aeb3726
BibTeX
@article{Kim2026,
author = {Kim, Jiwon and Oh, Jaeik and Jang, Dongjun and Shin, Seungjae and Lee, Soo-Jin and Lee, Sang Eun and Yang, Yoojin and Kim, Dohee and Choi, Ae Jin and Jung, Hae Rim and Oh, Yumi and Cho, Sung-Yup},
title = {Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {23},
doi = {10.1126/sciadv.aeb3726}
}
EUVIMED